Marker Therapeutics
Marker Therapeutics, based in Saint Paul, MN, is dedicated to advancing innovative T-cell therapies aimed at treating blood cancers and solid tumors. Their pioneering Multi-Antigen Recognizing (MAR-T) cell therapy leverages natural T cells to effectively identify and destroy heterogeneous tumors without genetic modifications.
The company's lead product candidate, MT-601, targets six specific tumor antigens and is currently being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. Marker Therapeutics' MAR-T cell technology, developed at Baylor College of Medicine, has demonstrated promising safety profiles and durable anti-tumor responses across various clinical indications.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.



